Navigation Links
Hemophilia Pipeline Overview - Once-a-week prophylaxis may soon become a reality
Date:12/13/2012

NEW YORK, Dec. 13, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Hemophilia Pipeline Overview – Once-a-week prophylaxis may soon become a reality 

http://www.reportlinker.com/p01055538/Hemophilia-Pipeline-Overview-–-Once-a-week-prophylaxis-may-soon-become-a-reality.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology 

Among the products for hemophilia A and B that are likely to reach the market within the next 4 years are modified recombinant factor replacements that could reduce injection frequencies significantly, making once-a-week prophylaxis a reality.Assess key pipeline products with regards to current gold-standard therapies.Identify the prospects faced by next-generation products in this niche market.Review and profile current key pipeline hemophilia A and B factor replacement products.Assess current unmet needs and challenges faced by pipeline products.

The most important unmet need is a longer half-life for clotting factors so that daily intravenous injections are no longer necessary. Moving from daily to weekly or fortnightly injections would improve patients' quality of life enormously.

Since longer clotting factor half-life is the major unmet need in hemophilia treatment, Datamonitor believes that novel recombinant compounds can only gain significant market share by either addressing the lack of long-acting recombinant factor IX therapeutics or by addressing the need for more competitively priced recombinant products.

Economy of scale plays a role when producing a biologic compound cost-effectively and established companies will have an advantage in this area; having the right infrastructure, production facilities, marketing channels, and sales force are important factors that will determine whether a company can successfully enter the hemophilia market.

Datamonitor's up to date key pipeline hemophilia A and B therapeutics profiles includes the latest clinical data and industry developments.Understand the most pressing unmet needs in hemophilia and how current pipeline products can gain significant market share by addressing them.Compare pipeline products with current gold-standard treatments and assess what they will have to do to deliver growth.

OVERVIEW

Catalyst

Summary

Clinical Pipeline Overview

A handful of key players dominate the market

Gene therapy looks hopeful but market entry is still not predicted for this decade

Current Gold-Standard Product Profiles

Kogenate FS (FVIII recombinant; Bayer): the gold-standard hemophilia A therapy

BeneFIX (FIX recombinant; Pfizer): the gold-standard hemophilia B therapy

Target product profile versus current level of attainment

Key Factor VIII Pipeline Products

NN7008 (turoctocog alfa; Novo Nordisk)

BIIB 031 (rFVIIIFc; Biogen Idec)

NN7088 (rFVIII, glycopegylated; Novo Nordisk)

BAY-94-9027 (recombinant PEGylated factor VIII; Bayer)

Clinical and commercial attractiveness for key hemophilia A pipeline products

Key Factor IX Pipeline Products

BAX 326 (recombinant PEGylated factor IX; Baxter)

CSL654 (rFIX-albumin fusion; CSL Behring)

BIIB 029 (rFIXFc; Biogen Idec)

NN7999 (rFIX, glycoPEGylated; Novo Nordisk)

Clinical and commercial attractiveness for key hemophilia B pipeline products

Bibliography

Journal articles and online sources

Appendix

Methodology

Datamonitor drug assessment for clinical and commercial attractiveness

TABLES

Table: Clinical pipeline key drugs for hemophilia A and B, November 2012

Table: Kogenate FS (recombinant Factor VIII; Bayer) – drug profile, 2012

Table: Kogenate FS (recombinant Factor VIII; Bayer) – drug profile, 2012

Table: Kogenate FS (rFVIII; Bayer) and BeneFIX (rFIX; Pfizer) vs the target product profile in previously treated patients, 2012

Table: Key events in the clinical development of NN7008 (turoctocog alfa; Novo Nordisk), 2012

Table: Key events in the clinical development of BIIB 031 (rFVIIIFc; Biogen Idec), 2012

Table: Key events for the clinical development of NN7088 (Novo Nordisk), 2012

Table: Key events for the clinical development of BAY-94-9027 (Bayer), 2012

Table: Key events for the clinical development of BAX 326 (Baxter), 2012

Table: Key events for the clinical development of CSL654 (CSL Behring), 2012

Table: Key events for the clinical development of BIIB 029 (rFIXFc; Biogen Idec), 2012

Table: Key events for the clinical development of NN7999 (Novo Nordisk), 2012

FIGURES

Figure: Clinical and commercial attractiveness for key hemophilia A pipeline drugs vs comparator Kogenate FS (rFVIII; Bayer), 2012

Figure: Breakdown of clinical and commercial attractiveness attributes for key hemophilia A pipeline drugs, 2012

Figure: Launch timeline for key hemophilia A pipeline drugs, 2012

Figure: Clinical and commercial attractiveness for key hemophilia B pipeline drugs vs comparator BeneFIX (rFIX; Pfizer), 2012

Figure: Breakdown of clinical and commercial attractiveness attributes for key hemophilia B pipeline drugs, 2012

Figure: Launch timeline for key hemophilia B pipeline drugs, 2012

Companies Mentioned

Arriva plc, CSL Behring, Hutchison 3G UK Limited, Imperial Tobacco Group PLC, Ipsen S.A., Nektar Therapeutics, Telstra Corporation Limited

To order this report:

Pathology Industry: Hemophilia Pipeline Overview – Once-a-week prophylaxis may soon become a reality  

CONTACT:
Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novo Nordisk introduces HemaGo, a mobile application to track hemophilia treatment, bleeding episodes and life events
2. Bayers Second Annual Virtual Walk for Hemophilia Raises Funds, Generates Excitement in the Hemophilia Community
3. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
4. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
5. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
6. Bausch + Lomb Product, Platform and Pipeline Innovations on Display at the Annual Meeting of the American Academy of Ophthalmology
7. Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
8. Neurostimulation Devices Market to 2018 - Technological Advances and Robust Pipeline with Multi-Indication Potential and Non-Invasive Therapies to Drive Growth
9. Epigenetics R&D Pipeline - Histone Deacetylases (HDACs) Offer the Most Promising Targets and Outnumber Other Classes of Epigenetic Targets
10. Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
11. Biopsy Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations ... Latin America . ... ... ... ...
(Date:6/23/2016)... The vast majority of dialysis patients currently ... are usually 3 times a week, with treatment times ... time, equipment preparation and wait time.  This regimen can ... patients who are elderly and frail.  Many elderly dialysis ... centers for some duration of time. Residents ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
Breaking Medicine News(10 mins):